Rezolute (Rezolute) Cash And Cash Equivalents : $12.50 Mil (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Rezolute Cash And Cash Equivalents?

Rezolute's quarterly cash and cash equivalents declined from Jun. 2023 ($16.04 Mil) to Sep. 2023 ($8.06 Mil) but then increased from Sep. 2023 ($8.06 Mil) to Dec. 2023 ($12.50 Mil).

Rezolute's annual cash and cash equivalents increased from Jun. 2021 ($41.05 Mil) to Jun. 2022 ($150.41 Mil) but then declined from Jun. 2022 ($150.41 Mil) to Jun. 2023 ($16.04 Mil).

Rezolute Cash And Cash Equivalents Historical Data

The historical data trend for Rezolute's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rezolute Cash And Cash Equivalents Chart

Rezolute Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash And Cash Equivalents

Get a 7-Day Free Trial

11.57

9.96

41.05

150.41

16.04

Rezolute Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															146.75	33.74	16.04	8.06	12.50

Rezolute Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Rezolute (NAS:RZLT) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Rezolute Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Rezolute's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Rezolute (Rezolute) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rezolute Inc (NAS:RZLT) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Shoreline Drive, Suite 500, Redwood City, CA, USA, 94065

Website

https://www.rezolutebio.com

Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.

Executives

Brian Kenneth Roberts	officer: Chief Medical Officer	C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Gil M Labrucherie	director	150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Wladimir Hogenhuis	director	60 LEVERONI COURT, NOVATO CA 94949
Nerissa Kreher	director	C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Handok, Inc.	10 percent owner	132, TEHERAN-RO, GANGNAM GU, SOUL M5 06235
Philippe Fauchet	director	C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Junghee Lim	director	C/O REZOLUTE, INC., 201 REDWOOD SHORE'S PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Genexine Inc.	10 percent owner	700 DAEWANGPANGYO-RO, KOREA PARKBLDG. B, BUNDANG-GU, SEONGNAM-SI, GYEONGGI-DO M5 13488
Seline E. Miller	officer: VP Finance & CAO	C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Young-jin Kim	director	49, BONGEUNSA-RO 49-GIL, GANGNAM-GU, SEOUL M5 06100
Young Chul Sung	director	101DONG 404HO, PARKTOWER APT. 69, SEOBINGGO-RO, YONGSAN-GU, SEOUL M5 04385
Keith A. Vendola	officer: Chief Financial Officer	111 LIVORNO WAY, REDWOOD CITY CA 94065
Xoma Corp	10 percent owner	2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
David F Welch	director	C/O INFINERA CORPORATION, 140 CASPIAN COURT, SUNNYVALE CA 94089
Morgan Fields	officer: Chief Accounting Officer	890 SANTA CRUZ AVE., MENLO PARK CA 94025